Comment from Biotechnology Innovation Organization

Summary: The Biotechnology Innovation Organization (BIO) supports the FDA's proposal to create a Plausible Mechanism Framework for individualized therapies, viewing it as a necessary evolution in regulatory science. They request additional clarity on operational details, including broader scope for modalities, clearer definitions, expanded CMC flexibilities, and better integration with existing regulatory pathways.